S17 Ep53: Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2– Metastatic Breast Cancer—What the Latest Data Really Tell Us
About this episode
Experts discuss the latest data on oral SERDs for treating HR+/HER2– metastatic breast cancer from the ASCO 2026 updates.
Highlights from the PER® CME activity "Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2− Metastatic Breast Cancer–What the Latest Data Really Tell Us" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below. In this podcast, experts Virginia Kaklamani, MD, DSc; Kamel Abou Hussein, MD; Javier Cortés, MD, PhD; and Seth A. Wander, MD, PhD, discuss American Society of Clinical Oncology (ASCO) 2026 updates about data for oral selective estrogen receptor degraders (SERDs) to treat metastatic, HR-positive breast cancer. Earn CME credit by completing the full accredited activity (available through June 29, 2027): https://www.gotoper.com/courses/oncology-town-hall-updates-from-chicago-oral-serds-in-hrher2-metastatic-breast-cancerwhat-the-latest-data-really-tell-us This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational…
Sponsors
Stemline Therapeutics, Inc.
More episodes of OncLive® On Air
- S17 Ep59: ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions
- S17 Ep58: DLBCL 2026 UPDATE
- S17 Ep57: Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC
- S17 Ep56: Navigating Systemic Therapy Selection and Sequencing in Advanced CSCC: With Neil D. Gross, MD, FACS
- S17 Ep55: Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis
- S17 Ep54: Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology
Explore listener stats, chart rankings, contacts and more on the OncLive® On Air podcast page.